How much revenue does Pacific Shuanglin Bio-pharmacy make?

Pacific Shuanglin Bio-pharmacy reported 2.65 billion CNY in revenue for fiscal year 2024, up 14.0% from 2.33 billion CNY in fiscal year 2023. In Q2 2025 revenue was 611.83 million CNY.

Where does Pacific Shuanglin Bio-pharmacy make most of its revenue?

China: 100% of revenue by region in fiscal year 2025, followed by Foreign (under 1%).

What companies are similar to Pacific Shuanglin Bio-pharmacy?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SS), Hunan Jingfeng Pharmaceutical Co.,Ltd. (000908.SZ), Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ), Chongqing Genrix Biopharmaceutical Co., Ltd. (688443.SS).

Pacific Shuanglin Bio-pharmacy Co., Ltd. (000403.SZ) Stock

About Pacific Shuanglin Bio-pharmacy Co., Ltd.

Pacific Shuanglin Bio-pharmacy Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of blood products in China and internationally. The company offers human serum albumin, human immunoglobulin (PH4), human immunoglobulin, hepatitis B human immunoglobulin, tetanus immunoglobulin, rabies immunoglobulin, human coagulation factor VIII, human fibrinogen,...

At a glance

Pacific Shuanglin Bio-pharmacy reported revenue of 2.65 billion CNY for fiscal year 2024, up 14.0% from fiscal year 2023, and net income of 745.32 million CNY. In Q2 2025 (the quarter ended June 30, 2025) revenue was 611.83 million CNY, down 12.7% from a year before. China was its largest region in fiscal year 2025, with 100% of revenue.

Figures from company filings; latest fiscal year ended December 31, 2024.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.